Health · Healthcare & Policy · 6 hrs ago

FDA authorizes Theraclion’s noninvasive device for treating vein reflux

FDA authorizes Theraclion’s noninvasive device for treating vein reflux

The FDA authorized Theraclion’s Sonovein device to treat superficial venous reflux in the great saphenous vein, a major cause of varicose veins.

The device uses focused ultrasound and treats veins without incisions or catheters.

Varicose veins affect about one third of adults, according to the information provided.

In a trial of 70 people at four sites in the US and Europe, 96.8% of treated veins were closed after one year.

The study reported no serious or unexpected adverse events and one mild event.

The authorization gives US patients and doctors access to a noninvasive treatment option for this condition.

Theraclion plans to set up treatment centers and provide physician training and support, while working toward insurance coverage.

1 source

Related

What people are saying

Martin DeterreTheraclion chief executive officer
This authorization marks the culmination of years of clinical and regulatory work and opens a defining new chapter for Theraclion. Sonovein enables entirely noninvasive vein treatment, without incisions or catheters. We are proud to bring this fundamental advance to US patients and physicians. I thank our teams, clinical investigators, partners, and shareholders, whose dedication and belief in our vision helped make this achievement possible. We also thank the FDA for its constructive engagement throughout the review process.
via News-Medical